06.05.24
The Montana Healthcare Foundation recently released its fourth annual Medicaid in Montana report on the state’s Medicaid program and its impact on the state budget, economy, and health.
On May 29, E&C Ranking Member Frank Pallone (D-NJ) announced the release of a report that he previously requested from the Government Accountability Office (GAO) on prior authorization practices for pediatric services by Medicaid
Nevada’s Division of Insurance (DOI) announced that it will require state-regulated health plans to apply manufacturer assistance to an enrollee’s cost-sharing obligations under a plan, except when a generic alternative is available
On May 15, 2024, the U.S. Securities and Exchange Commission (the “SEC”) adopted amendments to Regulation S-P (the “Data Privacy Amendments”), which governs the use of personal information by certain financial institutions.
On May 29, the American Clinical Laboratory Association (ACLA) sued the Food and Drug Administration (FDA) in an effort to vacate its recent final rule that will gradually phase out FDA’s long-standing policy of enforcement discretion for laboratory-developed tests
06.03.24
After many iterations over the years attempting to regulate the cryptocurrency space, the House of Representatives passed the Financial Innovation and Technology for the 21st Century Act, or FIT21 Act, on May 22, 2024.
05.30.24
To the likely surprise of providers of buy now, pay later (“BNPL”) financing, last week the Consumer Financial Protection Bureau (“CFPB”) issued an interpretive rule
On May 17, the Senate Finance Committee released a long-awaited white paper describing its legislative effort focused on bolstering chronic care through physician payment.
On May 21, the U.S. Court of Appeals for the District of Columbia Circuit upheld the right of pharmaceutical manufacturers to place at least some restrictions on the shipment of 340B drugs to contract pharmacies of 340B covered entities.
During its meeting on May 20, Maryland’s Prescription Drug Affordability Board (PDAB) unanimously voted to conduct cost reviews on six of eight products it was considering.